体内
吸入
体外
粒径
粒子(生态学)
生物医学工程
化学
色谱法
材料科学
干粉吸入器
纳米颗粒
吸入染毒
化学工程
微粒
作者
Yumiko Mizuno,Harald A. Butterweck,Barry Derham,Juha Kontturi,Joona Sundqvist,Madhusmita Priyadarshini Sahu,Markus Weiller,Alfred Weber,Rudolf Hartmann,Andreas Liebminger
标识
DOI:10.1016/j.jddst.2026.109166
摘要
Alpha-1 antitrypsin (AAT) deficiency is treated by AAT augmentation therapy, but standard intravenous infusions provide room for improvement in terms of increasing drug delivery to the lung and patient’s convenience. We developed a formulated dry powder for delivery of AAT using Nanoform’s proprietary technology (Nanoforming’ via the BioLine) to target the lungs directly using a dry powder inhaler (DPI). Human plasma AAT was formulated and dried into ∼1.7 μm mass median aerodynamic diameter (MMAD) particles containing L-leucine to enhance dispersibility. In vitro , the nanoformed AAT powder consisted of spherical, non-agglomerated particles that preserved native protein integrity (same as unprocessed AAT) and showed no loss of elastase inhibitory activity. Upon aerosolisation in a capsule-based DPI device, the formulation exhibited excellent performance: Emitted dose >90% and fine particle fraction approximately 80–85% (particles <5 μm), substantially higher than a prior spray-dried AAT powder (<50%). The nanoformed particles remained stable (no activity loss or aggregation) for ≥3 months at 25 °C. In vivo , intratracheal administration of nanoformed AAT in mice resulted in sustained measurable pulmonary exposure and preserved anti-neutrophil elastase activity while maintaining substantially lower systemic than pulmonary exposure. Pulmonary exposure profiles were broadly comparable between nanoformed dry-powder AAT and reconstituted nanoformed AAT, indicating that conversion into a dry-powder formulation did not substantially compromise in vivo performance. These results demonstrate that nanoforming enables efficient aerosolization and pulmonary delivery of AAT while preserving protein integrity and biological activity, supporting further development of inhaled AAT therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI